Radioimmunotherapy (RIT) allows for the delivery of high doses of therapeutic radiation to tumor cells while minimizing exposure to normal cells. RIT works by using engineered proteins called antibodies to home in on tumors in the body while carrying radioactive payloads to destroy the tumor cells. This form of therapeutic liquid radiation harnesses the power of immunotherapy to specifically target cancer cells with the potency of nuclear energy to create one of the most effective ways to obliterate all traces of tumor cells.
Y-mAbs takes a unique approach to RIT to allow for higher potency and greater safety to deliver therapeutic radiation to tumors using compartmental radioimmunotherapy.
Y-mAbs is developing compartmental therapy using our Breakthrough Therapy product omburtamab labeled with radioactive iodine. Omburtamab targets tumor antigen B7-H3, a cell surface protein found on neuroblastoma and most solid tumors. When neuroblastoma tumors metastasize to the leptomeninges (LM) or central nervous system (CNS), radio-labeled omburtamab can be directly injected in the CNS using an Ommaya catheter. This delivery of therapeutic liquid radiation directly into the CNS compartment allow for the treatment to directly reach the tumor, which could not have been done by systemic administration. Additional compartmental therapy is being developed for B7-H3 positive tumors in the CNS (DIPG) and in the peritoneum (DSCRT).